# Efficacy and Safety Proof of Concept Study in Patients With Parkinson's Disease and End-of-dose Motor Fluctuations

> **NCT01766258** · PHASE2 · COMPLETED · sponsor: **Orion Corporation, Orion Pharma** · enrollment: 117 (actual)

## Conditions studied

- Parkinson's Disease

## Interventions

- **DRUG:** ODM-101 65mg Carbidopa
- **DRUG:** ODM-101 105mg Carbidopa
- **DRUG:** Stalevo

## Key facts

- **NCT ID:** NCT01766258
- **Lead sponsor:** Orion Corporation, Orion Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-05
- **Primary completion:** 2012-08
- **Final completion:** 2012-09
- **Target enrollment:** 117 (ACTUAL)
- **Last updated:** 2013-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01766258

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01766258, "Efficacy and Safety Proof of Concept Study in Patients With Parkinson's Disease and End-of-dose Motor Fluctuations". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01766258. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*